Navigation Links
China Biologic Products Gains Financial Support from Shandong Provincial Government on the Improvement of Production Facilities
Date:1/14/2008

TAI'AN CITY, Shandong, China, Jan. 14 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (Pink sheets: CBPO) ("China Biologic" or the "Company"), one of the leading manufacturers of plasma-based pharmaceutical products in the People's Republic of China ("China" or the "PRC"), today announced that it was granted a RMB1.5 million (approximately US$0.2 million) award by the Shandong Provincial Government for use in the improvement of its plasma production facilities in accordance with Shandong's "Double Hundred Project" initiative.

The Double Hundred Project initiative was launched in January 2006 by Shandong Province, in response to China's Eleventh Five-year Development Plan. Through the Double Hundred Project, Shandong set up a special fund to develop what it identified as one hundred key products and one hundred key technology innovation centers in the province. The project provides, among other things, policy and financial support as well as quantitative government assessment to develop the chosen one hundred key products into eventually becoming, within five years, among China's top three products in terms of production capacity in their respective industries. Recognition of a product by the project also results in brand recognition for a manufacturer within Shandong Province and throughout China.

The Company's grant award was preceded by the Company's formal acceptance into the Double Hundred Project by the Shandong Economic and Trade Committee on December 21, 2007.

"We consider this award from the government as a strong endorsement of our continuous efforts in research and development and of our achievements in upgrading our production facilities to develop more technologically advanced plasma based products," said Mr. Stanley Wong, CEO of China Biologic. "We expect that support from the project will provide us with a competitive edge for our manufacturing technology and our products."

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's principal products are human albumin and immunoglobulin products that are used mainly to increase blood volume and for disease prevention and treatment.

Safe Harbor Statement

This press release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc., and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding the ability of the Company to achieve its commercial objectives, the business strategy, plans and objectives of the Company and its subsidiaries and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Stanley Wong

CEO

China Biologic Products, Inc.

Tel: +86-538-6202608

Email: IR@ctbb.com.cn

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the ... China , today announced that its board of directors ... of the plan from March 27, 2017 to March 27, 2018. The ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... MA (PRWEB) , ... March 23, 2017 , ... ... “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which ... disc polymer exhibits properties to gently absorb compressive forces and return to its ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):